3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Enrolling by invitation
1
Sponsor Class
INDUSTRY
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Breast
81
Thoracic
14
Gynecologic
12
Gastrointestinal
12
Head & Neck
10
Genitourinary
9
Dermatologic
5
Sarcoma
4
Other solid neoplasm
2
CNS
2
Plasma cell
1
Other hematologic neoplasm
1
Endocrine
1
Conditions
Advanced Solid Tumors
35
Advanced Solid Tumor
22
Solid Tumors
17
Mesothelioma
16
Solid Tumor
12
Mesothelioma, Malignant
11
Hematopoietic and Lymphatic System Neoplasm
10
Ovarian Neoplasms
7
Solid Tumor, Adult
5
Pancreatic Neoplasms
5
Malignant Solid Neoplasm
5
Solid Tumours
4
Lung Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Solid Tumour
4
Stomach Neoplasms
3
Small Cell Lung Carcinoma
3
Sarcoma
3
Kidney Neoplasms
3
Advanced or Metastatic Solid Tumors
3
Advanced Malignant Solid Tumors
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Thymus Neoplasms
2
Solid Tumor Malignancies
2
Solid Tumor Cancer
2
Retinoblastoma
2
Rectal Neoplasms
2
Neoplasms
2
Metastatic Solid Tumors
2
Interventions
pembrolizumab
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Other solid neoplasm
×
30 days
×
Clear all
NCT05579366
2026-05-26
RAINFOL-01
Genmab
Phase 1/2
Recruiting
884 enrolled
NCT06885424
2026-05-20
DESCENT-1
A2 Biotherapeutics Inc.
Enrolling by invitation
400 enrolled